Strata Critical Medical Q3 revenue beats estimates; announces $20 million buyback
SRTA•Strata Critical Medical reported Q3 revenue of $74.08 million, up 50% year over year and above the $72.67 million analyst estimate, and authorized a $20 million share repurchase program. It reiterated 2026 revenue guidance of $285 million to $295 million and adjusted EBITDA guidance of $33 million to $35 million.
1. Revenue and buyback
Q3 revenue rose 50% year over year to $74.08 million, beating the $72.67 million analyst estimate. Adjusted EBITDA more than doubled year over year, which the company attributed to acquisitions in its clinical segment. Strata authorized a $20 million share repurchase program.
2. 2026 outlook
Strata reiterated its 2026 revenue outlook of $285 million to $295 million and adjusted EBITDA outlook of $33 million to $35 million. It expects free cash flow, before aircraft and engine acquisitions, of $15 million to $22 million. Logistics revenue declined year over year, while clinical gross margin increased year over year but declined sequentially due to staff and training investments.
